ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 168 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2017. The put-call ratio across all filers is 1.04 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,207,190 | -34.0% | 1,231,827 | -6.4% | 0.01% | -43.8% |
| Q2 2023 | $1,829,379 | -36.4% | 1,316,100 | -27.3% | 0.02% | -42.9% |
| Q1 2023 | $2,877,758 | -34.7% | 1,809,911 | +156.0% | 0.03% | -24.3% |
| Q4 2022 | $4,404,934 | -18.1% | 707,052 | -12.0% | 0.04% | -17.8% |
| Q3 2022 | $5,381,000 | +1308.6% | 803,069 | +1238.4% | 0.04% | +1025.0% |
| Q2 2022 | $382,000 | -23.0% | 60,000 | -43.9% | 0.00% | 0.0% |
| Q1 2022 | $496,000 | -65.8% | 106,900 | -63.2% | 0.00% | -69.2% |
| Q4 2021 | $1,452,000 | +774.7% | 290,300 | +2010.2% | 0.01% | +550.0% |
| Q3 2021 | $166,000 | -86.9% | 13,757 | -77.1% | 0.00% | -85.7% |
| Q2 2021 | $1,271,000 | -81.0% | 60,065 | -67.0% | 0.01% | -92.9% |
| Q3 2019 | $6,673,000 | +3003.7% | 182,019 | +5474.9% | 0.20% | +988.9% |
| Q4 2017 | $215,000 | -22.7% | 3,265 | -83.7% | 0.02% | -61.7% |
| Q3 2016 | $278,000 | – | 20,062 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $22,344,000 | 10.09% |
| Altium Capital Management LP | 2,515,785 | $12,579,000 | 3.47% |
| Deep Track Capital, LP | 5,641,668 | $28,208,000 | 1.99% |
| Paradigm Biocapital Advisors LP | 839,257 | $4,196,000 | 1.20% |
| SABBY MANAGEMENT, LLC | 940,400 | $4,702,000 | 0.68% |
| Monaco Asset Management SAM | 500,000 | $2,500,000 | 0.62% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,000,000 | $25,000,000 | 0.52% |
| CVI Holdings, LLC | 1,460,595 | $7,303,000 | 0.48% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $13,566,000 | 0.38% |
| Rhenman & Partners Asset Management AB | 1,000,000 | $4,960,000 | 0.33% |